Equities analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to post earnings per share (EPS) of $0.24 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Myriad Genetics’ earnings. The lowest EPS estimate is $0.22 and the highest is $0.26. Myriad Genetics posted earnings of $0.26 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 7.7%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 6th.
On average, analysts expect that Myriad Genetics will report full-year earnings of $1.05 per share for the current fiscal year, with EPS estimates ranging from $1.03 to $1.10. For the next fiscal year, analysts anticipate that the firm will report earnings of $1.23 per share, with EPS estimates ranging from $1.09 to $1.52. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Myriad Genetics.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. During the same quarter last year, the company posted $0.23 earnings per share. Myriad Genetics’s quarterly revenue was up 7.2% on a year-over-year basis.
In other news, insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.70% of the company’s stock.
Several large investors have recently modified their holdings of MYGN. Teachers Advisors LLC boosted its holdings in shares of Myriad Genetics by 1.1% during the first quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock worth $2,245,000 after acquiring an additional 1,287 shares during the period. Aperio Group LLC boosted its holdings in shares of Myriad Genetics by 4.6% during the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock worth $313,000 after acquiring an additional 534 shares during the period. Hartford Investment Management Co. bought a new stake in shares of Myriad Genetics during the second quarter worth approximately $258,000. Municipal Employees Retirement System of Michigan boosted its holdings in shares of Myriad Genetics by 3.1% during the second quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock worth $416,000 after acquiring an additional 490 shares during the period. Finally, NGAM Advisors L.P. boosted its holdings in shares of Myriad Genetics by 15.1% during the second quarter. NGAM Advisors L.P. now owns 109,275 shares of the company’s stock worth $2,824,000 after acquiring an additional 14,375 shares during the period.
Myriad Genetics (NASDAQ:MYGN) traded down $0.81 during trading on Friday, reaching $33.82. The company had a trading volume of 652,697 shares, compared to its average volume of 1,054,122. Myriad Genetics has a fifty-two week low of $15.15 and a fifty-two week high of $37.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The company has a market capitalization of $2,341.73, a PE ratio of 31.03, a P/E/G ratio of 2.14 and a beta of 0.25.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/03/zacks-brokerages-expect-myriad-genetics-inc-mygn-will-post-earnings-of-0-24-per-share.html.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.